Inozyme Pharma Inc [INZY] stock is trading at $1.15, up 8.49%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The INZY shares have gain 17.28% over the last week, with a monthly amount glided 26.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Inozyme Pharma Inc [NASDAQ: INZY] stock has seen the most recent analyst activity on December 12, 2024, when Raymond James initiated its Outperform rating and assigned the stock a price target of $26. Previously, Stifel started tracking the stock with Buy rating on September 12, 2024, and set its price target to $16. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $14 on May 30, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $6 on March 23, 2023. Jefferies started tracking with a Hold rating for this stock on May 26, 2022, and assigned it a price target of $5. In a note dated February 07, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $33 on this stock.
Inozyme Pharma Inc [INZY] stock has fluctuated between $0.72 and $6.24 over the past year. Currently, Wall Street analysts expect the stock to reach $14.67 within the next 12 months. Inozyme Pharma Inc [NASDAQ: INZY] shares were valued at $1.15 at the most recent close of the market. An investor can expect a potential return of 1175.65% based on the average INZY price forecast.
Analyzing the INZY fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is -1.15 and Total Capital is -1.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0364 points at the first support level, and at 0.9228 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2318, and for the 2nd resistance point, it is at 1.3136.
Ratios To Look Out For
For context, Inozyme Pharma Inc’s Current Ratio is 3.56. In addition, the Quick Ratio stands at 3.56 and the Cash Ratio stands at 0.62.
Transactions by insiders
Recent insider trading involved Treco Douglas A, CEO & Chairman, that happened on Apr 02 ’25 when 8819.0 shares were sold.
